Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(12): 1035-1038
DOI: 10.1590/0004-282X20160160
HISTORICAL NOTE

Charcot, Mitchell and Lees: neurology free thinkers and their experiences of psychoactive drugs

Charcot, Mitchell e Lees: livres-pensadores da neurologia e suas experiências com drogas psico-ativas
Hélio A. G. Teive
1   Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Medicina Interna, Serviço de Neurologia, Unidade de Distúrbios dos Movimentos, Curitiba PR, Brasil;
,
Francisco M.B. Germiniani
1   Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Medicina Interna, Serviço de Neurologia, Unidade de Distúrbios dos Movimentos, Curitiba PR, Brasil;
,
Pedro A. Kowacs
2   Universidade Federal do Paraná, Hospital de Clínicas, Serviço de Neurologia, Unidade de Dor de Cabeça, Curitiba PR, Brasil;
,
Renato P. Munhoz
3   University Health Network, Toronto Western Hospital, Gloria and Morton Shulman Movement Disorders, Toronto, ON, Canada.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Three world-famous neurologists, Charcot and Mitchell, in the 19th century, and Lees, in this century, all of whom had great scientific curiosity, experimented with the psychoactive drugs hashish, mescal and yagé, respectively, in an attempt to increase their knowledge of neurological diseases and how the brain works.

RESUMO

Três mundialmente famosos neurologistas, Charcot e Mitchell, no século XIX, e Lees neste século, tiveram eles mesmos, experiências com drogas psico-ativas, com haxixe, mescalina e yagé, respectivamente, demonstrando a sua intensa curiosidade científica, na tentativa de aprimorar o seu conhecimento da função cerebral e das doenças neurológicas.

neurology - psychotropic drugs, brain
neurologia - psicotrópicos - encéfalo


Publication History

Received: 14 August 2016

Accepted: 05 September 2016

Article published online:
06 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Brust JC. Neurologic complications of illicit drug abuse. Continuum (Minneap Minn) 2014;20(3 Neurology of Systemic Disease):642-56. doi:10.1212/01.CON.0000450971.99322.cd
  • 2 Pascoli V, Terrier J, Hiver A, Lüscher C. Sufficiency of mesolimbic dopamine neuron stimulation for the progression to addiction. Neuron. 2015;88(5):1054-66. doi:10.1016/j.neuron.2015.10.017
  • 3 Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L et al. Medical marijuana in neurology. Expert Rev Neurother. 2014;14(12):1453-65. doi:10.1586/14737175.2014.985209
  • 4 Goetz GG, Bonduelle M, Gelfand T. Charcot: constructing neurology. New York: Oxford University Press; 1995.
  • 5 Goetz GG. Jean-Martin Charcot and Silas Weir Mitchell. Neurology. 1997;48(4):1128-32.
  • 6 Meige H. Charcot artiste. Nouvelle Iconographie de la Salpêtriére. 1898;11:489-516.
  • 7 Mitchell SW. Remarks on the effects of anhelonium lewinii (the mescal button). Br Med J. 1896;2(1875):1625-9.
  • 8 Lees AJ. Mentored by a madman: the William Burroughs experiment. London: Nothing Hill; 2016.
  • 9 Sorensen AA, Weedon D. Productivity and impact of the top 100 cited Parkinson’s disease investigators since 1985. J Parkinsons Dis. 2011;1(1):3-13. doi:10.3233/JPD-2011-10021
  • 10 Ponce FA, Lozano AM. The most cited works in Parkinson´s disease. Mov Disord. 2011;26(3):380-90. doi:10.1002/mds.23445